St. Maris Pharma

St. Maris Pharma is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative therapies for metabolic diseases. The company focuses on multi-target agonists, particularly in the incretin space, targeting conditions such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Their lead program, SM-1, is a long-acting GLP-1/GIP/GCGR triple receptor agonist designed to provide superior weight loss and glycemic control compared to existing mono- or dual-agonists. St. Maris leverages a proprietary peptide engineering platform to optimize the pharmacological profiles and dosing schedules of its candidates. The company is led by a management team with significant experience in global drug development and is supported by leading venture capital investors.